Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Intellia Therapeutics Analyst Ratings and Price Targets | NASDAQ:NTLA | Benzinga
Intellia Therapeutics Inc has a consensus price target of $46.54 based on the ratings of 27 analysts. The high is $116 issued by EF Hutton on February 24, 2023. The low is $10 issued by Wedbush on May 19, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co. on June 16, 2025, June 3, 2025, and May 29, 2025, respectively. With an average price target of $38 between HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co., there's an implied 292.97% upside for Intellia Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
Wedbush
Guggenheim
Citigroup
1calculated from analyst ratings
Analyst Ratings for Intellia Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/16/2025 | Buy Now | 210.24% | HC Wainwright & Co. | Mitchell Kapoor46% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2025 | Buy Now | 458.43% | Canaccord Genuity | Whitney Ijem57% | $74 → $54 | Maintains | Buy | Get Alert |
| 05/29/2025 | Buy Now | 210.24% | HC Wainwright & Co. | Mitchell Kapoor46% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/20/2025 | Buy Now | 210.24% | HC Wainwright & Co. | Mitchell Kapoor46% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/19/2025 | Buy Now | 3.41% | Wedbush | David Nierengarten61% | $10 → $10 | Reiterates | Neutral → Neutral | Get Alert |
| 05/12/2025 | Buy Now | 365.36% | Guggenheim | Debjit Chattopadhyay55% | $55 → $45 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | 3.41% | Citigroup | David Lebowitz55% | $14 → $10 | Maintains | Neutral | Get Alert |
| 05/09/2025 | Buy Now | 603.21% | Chardan Capital | Geulah Livshits49% | $68 → $68 | Maintains | Buy | Get Alert |
| 04/21/2025 | Buy Now | 117.17% | Wolfe Research | Andy Chen48% | → $21 | Upgrade | Peer Perform → Outperform | Get Alert |
| 03/05/2025 | Buy Now | 210.24% | HC Wainwright & Co. | Mitchell Kapoor46% | → $30 | Initiates | → Buy | Get Alert |
| 03/04/2025 | Buy Now | 417.06% | Truist Securities | Joon Lee76% | $90 → $50 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 168.87% | Barclays | Gena Wang51% | $55 → $26 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 44.78% | Citigroup | David Lebowitz55% | $12 → $14 | Maintains | Neutral | Get Alert |
| 02/28/2025 | Buy Now | 417.06% | Wells Fargo | Yanan Zhu42% | $60 → $50 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 603.21% | Chardan Capital | Geulah Livshits49% | $91 → $68 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 34.44% | JP Morgan | Brian Cheng39% | $45 → $13 | Downgrade | Overweight → Neutral | Get Alert |
| 01/27/2025 | Buy Now | 13.75% | Morgan Stanley | Terence Flynn66% | $56 → $11 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 01/14/2025 | Buy Now | 24.1% | Goldman Sachs | Salveen Richter52% | $19 → $12 | Maintains | Neutral | Get Alert |
| 01/13/2025 | Buy Now | 313.65% | Oppenheimer | Jay Olson60% | $60 → $40 | Maintains | Outperform | Get Alert |
| 01/10/2025 | Buy Now | 520.48% | Wells Fargo | Yanan Zhu42% | $70 → $60 | Maintains | Overweight | Get Alert |
| 01/10/2025 | Buy Now | 417.06% | BMO Capital | Kostas Biliouris34% | $70 → $50 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | 830.71% | Canaccord Genuity | Whitney Ijem57% | $90 → $90 | Maintains | Buy | Get Alert |
| 11/18/2024 | Buy Now | 623.89% | Wells Fargo | Yanan Zhu42% | $80 → $70 | Maintains | Overweight | Get Alert |
| 11/18/2024 | Buy Now | 44.78% | Wedbush | David Nierengarten61% | $14 → $14 | Reiterates | Neutral → Neutral | Get Alert |
| 11/18/2024 | Buy Now | 841.05% | Chardan Capital | Geulah Livshits49% | $88 → $91 | Maintains | Buy | Get Alert |
| 11/11/2024 | Buy Now | 520.48% | Oppenheimer | Jay Olson60% | $70 → $60 | Maintains | Outperform | Get Alert |
| 11/08/2024 | Buy Now | 468.77% | Barclays | Gena Wang51% | $76 → $55 | Maintains | Overweight | Get Alert |
| 10/25/2024 | Buy Now | 96.48% | Citigroup | David Lebowitz55% | $25 → $19 | Maintains | Neutral | Get Alert |
| 10/25/2024 | Buy Now | 106.83% | Goldman Sachs | Salveen Richter52% | $31 → $20 | Maintains | Neutral | Get Alert |
| 10/25/2024 | Buy Now | 86.14% | Baird | Jack Allen 37% | $24 → $18 | Maintains | Neutral | Get Alert |
| 10/24/2024 | Buy Now | 810.03% | Chardan Capital | Geulah Livshits49% | $94 → $88 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | 458.43% | RBC Capital | Luca Issi44% | $54 → $54 | Reiterates | Outperform → Outperform | Get Alert |
| 09/17/2024 | Buy Now | 323.99% | Jones Trading | Debanjana Chatterjee51% | → $41 | Initiates | → Buy | Get Alert |
| 09/11/2024 | Buy Now | 561.84% | Stifel | Dae Gon Ha49% | $80 → $64 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 468.77% | JP Morgan | Brian Cheng39% | $61 → $55 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | 458.43% | RBC Capital | Luca Issi44% | $60 → $54 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | 654.91% | Canaccord Genuity | Whitney Ijem57% | $73 → $73 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 572.18% | Cantor Fitzgerald | Rick Bienkowski28% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/24/2024 | Buy Now | 1140.95% | Truist Securities | Joon Lee76% | $120 → $120 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 572.18% | Cantor Fitzgerald | Rick Bienkowski28% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/04/2024 | Buy Now | 572.18% | Cantor Fitzgerald | Rick Bienkowski28% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 199.9% | Citigroup | David Lebowitz55% | $31 → $29 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 623.89% | BMO Capital | Kostas Biliouris34% | $62 → $70 | Maintains | Outperform | Get Alert |
| 04/23/2024 | Buy Now | 199.9% | Wedbush | David Nierengarten61% | $29 → $29 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | Buy Now | 230.92% | Goldman Sachs | Salveen Richter52% | → $32 | Downgrade | Buy → Neutral | Get Alert |
| 02/23/2024 | Buy Now | 654.91% | Canaccord Genuity | Whitney Ijem57% | $72 → $73 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen48% | — | Initiates | → Peer Perform | Get Alert |
| 11/13/2023 | Buy Now | 623.89% | Oppenheimer | Jay Olson60% | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/13/2023 | Buy Now | 779.01% | Morgan Stanley | Terence Flynn66% | $90 → $85 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | 541.16% | BMO Capital | Kostas Biliouris34% | $64 → $62 | Maintains | Outperform | Get Alert |
| 11/10/2023 | Buy Now | 623.89% | RBC Capital | Luca Issi44% | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/10/2023 | Buy Now | 1306.41% | Goldman Sachs | Salveen Richter52% | $157 → $136 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 489.45% | Raymond James | Steven Seedhouse57% | $78 → $57 | Maintains | Outperform | Get Alert |
| 09/13/2023 | Buy Now | 572.18% | Cantor Fitzgerald | Rick Bienkowski28% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 572.18% | Cantor Fitzgerald | Rick Bienkowski28% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 572.18% | Cantor Fitzgerald | Rick Bienkowski28% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2023 | Buy Now | 830.71% | Barclays | Gena Wang51% | $86 → $90 | Maintains | Overweight | Get Alert |
| 08/07/2023 | Buy Now | 572.18% | Canaccord Genuity | Whitney Ijem57% | $66 → $65 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | 1006.51% | Chardan Capital | Geulah Livshits49% | → $107 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | 313.65% | Citigroup | David Lebowitz55% | $44 → $40 | Maintains | Neutral | Get Alert |
| 08/04/2023 | Buy Now | 830.71% | Barclays | Gena Wang51% | $148 → $90 | Maintains | Overweight | Get Alert |
| 06/13/2023 | Buy Now | 841.05% | B of A Securities | Greg Harrison48% | $89 → $91 | Maintains | Buy | Get Alert |
| 06/13/2023 | Buy Now | 1006.51% | Chardan Capital | Geulah Livshits49% | $111 → $107 | Maintains | Buy | Get Alert |
| 06/13/2023 | Buy Now | 685.94% | Credit Suisse | Richard Law46% | → $76 | Reiterates | Outperform → Outperform | Get Alert |
| 05/08/2023 | Buy Now | 355.02% | Citigroup | David Lebowitz55% | $39 → $44 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | 830.71% | Oppenheimer | Jay Olson60% | $93 → $90 | Maintains | Outperform | Get Alert |
| 05/08/2023 | Buy Now | 789.35% | Morgan Stanley | Terence Flynn66% | $83 → $86 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 561.84% | BMO Capital | Kostas Biliouris34% | $57 → $64 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 706.62% | Raymond James | Steven Seedhouse57% | $94 → $78 | Maintains | Outperform | Get Alert |
| 04/13/2023 | Buy Now | 582.52% | Canaccord Genuity | Whitney Ijem57% | → $66 | Initiates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | 716.96% | JP Morgan | Brian Cheng39% | $82 → $79 | Maintains | Overweight | Get Alert |
| 03/21/2023 | Buy Now | 458.43% | Bernstein | William Pickering38% | → $54 | Initiates | → Outperform | Get Alert |
| 03/14/2023 | Buy Now | 489.45% | BMO Capital | Kostas Biliouris34% | $54 → $57 | Upgrade | Market Perform → Outperform | Get Alert |
| 02/27/2023 | Buy Now | 1047.88% | Chardan Capital | Geulah Livshits49% | $129 → $111 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 685.94% | Credit Suisse | Richard Law46% | $88 → $76 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 861.74% | Oppenheimer | Jay Olson60% | $115 → $93 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 334.33% | Baird | Jack Allen 37% | $58 → $42 | Maintains | Neutral | Get Alert |
| 02/24/2023 | Buy Now | 1099.59% | EF Hutton | Michael King43% | $123 → $116 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 872.08% | Raymond James | Steven Seedhouse57% | $124 → $94 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 592.86% | Cantor Fitzgerald | Rick Bienkowski28% | → $67 | Initiates | → Overweight | Get Alert |
| 01/24/2023 | Buy Now | 303.31% | Citigroup | David Lebowitz55% | $48 → $39 | Upgrade | Sell → Neutral | Get Alert |
| 01/23/2023 | Buy Now | 768.67% | SVB Leerink | Mani Foroohar50% | $86 → $84 | Maintains | Outperform | Get Alert |
| 01/19/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan47% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 01/04/2023 | Buy Now | 1140.95% | Wells Fargo | Yanan Zhu42% | $135 → $120 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 810.03% | Credit Suisse | Richard Law46% | $109 → $88 | Maintains | Outperform | Get Alert |
| 12/02/2022 | Buy Now | 789.35% | SVB Leerink | Mani Foroohar50% | $90 → $86 | Maintains | Outperform | Get Alert |
| 11/15/2022 | Buy Now | 1234.02% | Chardan Capital | Geulah Livshits49% | $121 → $129 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 1171.98% | EF Hutton | Michael King43% | $130 → $123 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 758.32% | Morgan Stanley | Terence Flynn66% | $84 → $83 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 1182.32% | Raymond James | Steven Seedhouse57% | $127 → $124 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 1027.2% | Credit Suisse | Richard Law46% | $101 → $109 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 1151.29% | Chardan Capital | Geulah Livshits49% | $146 → $121 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 1244.36% | EF Hutton | Michael King43% | → $130 | Initiates | → Buy | Get Alert |
| 10/11/2022 | Buy Now | 768.67% | Morgan Stanley | Terence Flynn66% | → $84 | Initiates | → Overweight | Get Alert |
| 09/21/2022 | Buy Now | 779.01% | JP Morgan | Brian Cheng39% | → $85 | Initiates | → Overweight | Get Alert |
| 09/19/2022 | Buy Now | 1047.88% | JMP Securities | Silvan Tuerkcan47% | $106 → $111 | Maintains | Market Outperform | Get Alert |
| 09/19/2022 | Buy Now | 1533.92% | SVB Leerink | Mani Foroohar50% | $152 → $158 | Maintains | Outperform | Get Alert |
| 09/01/2022 | Buy Now | 417.06% | Citigroup | David Lebowitz55% | → $50 | Initiates | → Sell | Get Alert |
| 08/05/2022 | Buy Now | 1471.87% | SVB Leerink | Mani Foroohar50% | $155 → $152 | Maintains | Outperform | Get Alert |
| 08/05/2022 | Buy Now | 1409.82% | Chardan Capital | Geulah Livshits49% | $172 → $146 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Intellia Therapeutics (NTLA) stock?
The latest price target for Intellia Therapeutics (NASDAQ:NTLA) was reported by HC Wainwright & Co. on June 16, 2025. The analyst firm set a price target for $30.00 expecting NTLA to rise to within 12 months (a possible 210.24% upside). 39 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Intellia Therapeutics (NTLA)?
The latest analyst rating for Intellia Therapeutics (NASDAQ:NTLA) was provided by HC Wainwright & Co., and Intellia Therapeutics reiterated their buy rating.
When was the last upgrade for Intellia Therapeutics (NTLA)?
The last upgrade for Intellia Therapeutics Inc happened on April 21, 2025 when Wolfe Research raised their price target to $21. Wolfe Research previously had a peer perform for Intellia Therapeutics Inc.
When was the last downgrade for Intellia Therapeutics (NTLA)?
The last downgrade for Intellia Therapeutics Inc happened on February 28, 2025 when JP Morgan changed their price target from $45 to $13 for Intellia Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Intellia Therapeutics (NTLA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intellia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intellia Therapeutics was filed on June 16, 2025 so you should expect the next rating to be made available sometime around June 16, 2026.
Is the Analyst Rating Intellia Therapeutics (NTLA) correct?
While ratings are subjective and will change, the latest Intellia Therapeutics (NTLA) rating was a reiterated with a price target of $30.00 to $30.00. The current price Intellia Therapeutics (NTLA) is trading at is $9.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
